FR 143430
Latest Information Update: 28 May 2001
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 30 Oct 1998 New profile
- 30 Oct 1998 Preclinical development for Cancer in Japan (Unknown route)